Bictegravir/emtricitabine/tenofovir-alafenamide/mirtazapineLack of efficacy: case report

被引:0
|
作者
机构
关键词
D O I
10.1007/s40278-025-79085-4
中图分类号
学科分类号
摘要
引用
收藏
页码:115 / 115
相关论文
共 50 条
  • [35] Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
    Squillace, Nicola
    Ricci, Elena
    Maggi, Paolo
    Taramasso, Lucia
    Menzaghi, Barbara
    De Socio, Giuseppe Vittorio
    Piconi, Stefania
    Maurizio Celesia, Benedetto
    Orofino, Giancarlo
    Sarchi, Eleonora
    Pellicano, Giovanni Francesco
    Simeone, Filomena
    Valsecchi, Laura
    Bandera, Alessandra
    Cenderello, Giovanni
    Attala, Letizia
    Angioni, Goffredo
    Falasca, Katia
    Cascio, Antonio
    Bargiacchi, Olivia
    Di Biagio, Antonio
    Bonfanti, Paolo
    PLOS ONE, 2023, 18 (08):
  • [36] Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV
    Tempestilli, Massimo
    D'Avolio, Antonio
    De Nicolo, Amedeo
    Agrati, Chiara
    Antinori, Andrea
    Cicalini, Stefania
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (12) : 3320 - 3322
  • [38] Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance
    Shafran, Stephen D.
    Hughes, Christine A.
    HIV MEDICINE, 2023, 24 (03) : 361 - 365
  • [39] Resistance analyses of bictegravir/emtricitabine/tenofovir alafenamide switch studies
    Schembri, G.
    Andreatta, K.
    Willkom, M.
    Martin, R.
    Chang, S.
    Martin, H.
    Graham, H.
    Quirk, E.
    White, K.
    HIV MEDICINE, 2018, 19 : S28 - S28